Insulin Resistance and Statin Treatment in Renal Transplant Recipients and Patients with Chronic Kidney Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501068-16-00

Acronym

INSTA

Enrollment

Registered

2022-09-26

Start date

2022-12-14

Completion date

2025-01-23

Last updated

2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin resistance

Brief summary

Insulin sensitivity assessed by hyperinsulinemic euglycemic glucose clamp

Interventions

DRUGCARBOHYDRATES

DRUGPOTASSIUM CHLORIDE

DRUGPravastatin Sandoz 40 mg tabletter

DRUGINSULIN (HUMAN)

DRUGName: Placebotablet 8 mm. Content supplied in the document Placebo Cataloging Form RAP 8 mm.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Insulin sensitivity assessed by hyperinsulinemic euglycemic glucose clamp	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026